BACKGROUND: Deep brain stimulation (DBS) is a well-established treatment for Parkinson's disease (PD). Optimization of DBS settings can be a challenge due to the number of variables that must be considered, including presence of multiple motor signs, side effects, and battery life. METHODS: Nine PD subjects visited the clinic for programming at approximately 1, 2, and 4 months post-surgery. During each session, various stimulation settings were assessed and subjects performed motor tasks while wearing a motion sensor to quantify tremor and bradykinesia. At the end of each session, a clinician determined final stimulation settings using standard practices. Sensor-based ratings of motor symptom severities collected during programming were then used to develop two automated programming algorithms--one to optimize symptom benefit and another to optimize battery life. Therapeutic benefit was compared between the final clinician-determined DBS settings and those calculated by the automated algorithm. RESULTS: Settings determined using the symptom optimization algorithm would have reduced motor symptoms by an additional 13 percentage points when compared to clinician settings, typically at the expense of increased stimulation amplitude. By adding a battery life constraint, the algorithm would have been able to decrease stimulation amplitude by an average of 50% while maintaining the level of therapeutic benefit observed using clinician settings for a subset of programming sessions. CONCLUSIONS: Objective assessment in DBS programming can identify settings that improve symptoms or obtain similar benefit as clinicians with improvement in battery life. Both options have the potential to improve post-operative patient outcomes.
BACKGROUND: Deep brain stimulation (DBS) is a well-established treatment for Parkinson's disease (PD). Optimization of DBS settings can be a challenge due to the number of variables that must be considered, including presence of multiple motor signs, side effects, and battery life. METHODS: Nine PD subjects visited the clinic for programming at approximately 1, 2, and 4 months post-surgery. During each session, various stimulation settings were assessed and subjects performed motor tasks while wearing a motion sensor to quantify tremor and bradykinesia. At the end of each session, a clinician determined final stimulation settings using standard practices. Sensor-based ratings of motor symptom severities collected during programming were then used to develop two automated programming algorithms--one to optimize symptom benefit and another to optimize battery life. Therapeutic benefit was compared between the final clinician-determined DBS settings and those calculated by the automated algorithm. RESULTS: Settings determined using the symptom optimization algorithm would have reduced motor symptoms by an additional 13 percentage points when compared to clinician settings, typically at the expense of increased stimulation amplitude. By adding a battery life constraint, the algorithm would have been able to decrease stimulation amplitude by an average of 50% while maintaining the level of therapeutic benefit observed using clinician settings for a subset of programming sessions. CONCLUSIONS: Objective assessment in DBS programming can identify settings that improve symptoms or obtain similar benefit as clinicians with improvement in battery life. Both options have the potential to improve post-operative patient outcomes.
Authors: Michael S Okun; Michele Tagliati; Michael Pourfar; Hubert H Fernandez; Ramon L Rodriguez; Ron L Alterman; Kelly D Foote Journal: Arch Neurol Date: 2005-06-13
Authors: Dustin A Heldman; Joseph P Giuffrida; Robert Chen; Megan Payne; Filomena Mazzella; Andrew P Duker; Alok Sahay; Sang Jin Kim; Fredy J Revilla; Alberto J Espay Journal: Mov Disord Date: 2011-04-29 Impact factor: 10.338
Authors: Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: Dustin A Heldman; Alberto J Espay; Peter A LeWitt; Joseph P Giuffrida Journal: Parkinsonism Relat Disord Date: 2014-03-05 Impact factor: 4.891
Authors: Brad A Racette; Gill Nelson; Wendy W Dlamini; Pradeep Prathibha; Jay R Turner; Mwiza Ushe; Harvey Checkoway; Lianne Sheppard; Susan Searles Nielsen Journal: Environ Health Date: 2021-03-15 Impact factor: 7.123
Authors: Jessica Frey; Jackson Cagle; Kara A Johnson; Joshua K Wong; Justin D Hilliard; Christopher R Butson; Michael S Okun; Coralie de Hemptinne Journal: Front Neurol Date: 2022-03-09 Impact factor: 4.003
Authors: Dustin A Heldman; Christopher L Pulliam; Enrique Urrea Mendoza; Maureen Gartner; Joseph P Giuffrida; Erwin B Montgomery; Alberto J Espay; Fredy J Revilla Journal: Neuromodulation Date: 2015-12-01
Authors: Gordon Duffley; Barbara J Lutz; Aniko Szabo; Adrienne Wright; Christopher W Hess; Adolfo Ramirez-Zamora; Pamela Zeilman; Shannon Chiu; Kelly D Foote; Michael S Okun; Christopher R Butson Journal: JAMA Neurol Date: 2021-08-01 Impact factor: 29.907
Authors: Josien C van den Noort; Rens Verhagen; Kees J van Dijk; Peter H Veltink; Michelle C P M Vos; Rob M A de Bie; Lo J Bour; Ciska T Heida Journal: Ann Biomed Eng Date: 2017-07-19 Impact factor: 3.934
Authors: Gökçe Kilinçalp; Anne-Christine Sjöström; Barbro Eriksson; Björn Holmberg; Radu Constantinescu; Filip Bergquist Journal: J Pers Med Date: 2022-01-02